Protagonist Therapeutics, Inc. (PTGX) is an innovative biopharmaceutical company focused on developing and commercializing oral peptide drugs. Founded in 2001, the company has its headquarters in Newark, California with additional offices in Queensland, Australia. Protagonist Therapeutics uses a proprietary technology platform to design and develop its oral peptide drugs, advancing novel therapeutic solutions to treat diseases with significant unmet medical needs.
The company operates under the leadership of Dinesh V. Patel, Ph.D., who serves as the President and Chief Executive Officer. Driven by seasoned scientists and drug innovators, PTGX is combining deep expertise in peptide chemistry, structural biology, and molecular pharmacology to transform the healthcare landscape.
Protagonist Therapeutics specializes in creating orally stable peptides that can address significant health issues, thereby providing an alternative to injectable therapies. This focus on oral peptides reflects the company's aim of improving patients’ quality of life by developing more easily administrable medications.
The company’s portfolio of drug candidates is targeting rare diseases, including inflammatory bowel disease (IBD), chronic iron overload, and other rare gastrointestinal diseases. PTG-300, an injectable hepcidin mimetic, is one of its leading drug candidates, currently in clinical trials. It addresses the treatment of rare hematologic disorders - thus, indicating the company's flexibility in developing both oral and injectable peptides.
Protagonist Therapeutics is marked by its rigorous research and dedication to driving scientific advancements. Its approach combines in-house innovation with strategic collaborations and partnerships with industry leaders in the biopharmaceutical space. This strategy has enabled the company to increase its scientific capabilities and market reach.
Consistent with its focused business strategy and responsible stewardship, PTGX maintains a commitment to corporate social responsibility. It underscores its dedication to ethical practices in all aspects of the business and its work towards minimizing the potential environmental impact of its operations.
Cultivating a dynamic and collaborative culture, Protagonist Therapeutics encourages innovation and creativity among its team. The company is dedicated to creating an inclusive environment where everyone feels respected and could contribute to their fullest potential.
In sum, Protagonist Therapeutics, Inc. (PTGX) merges innovative science and patient-centric focus, dedicating itself to advancing the field of peptide therapeutics and ultimately improving patients' lives. As it continues its pursuit of groundbreaking treatments, PTGX is poised to establish a new standard in the biopharmaceutical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Pictet Asset Management Holding SA reduced its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 16.9% in the third quarter, while other institutional investors like BlackRock Inc. and Johnson & Johnson increased their positions. Analyst sentiment remains largely positive, with a "Buy" average rating and an average price target of $166.67. The company recently reported strong quarterly earnings, beating analyst expectations for both EPS and revenue.
Wall Street Zen has upgraded Protagonist Therapeutics (NASDAQ:PTGX) to a "Strong-Buy" rating, aligning with an overall "Buy" consensus and an average price target of $166.67 from analysts. The company surpassed quarterly earnings expectations, reporting an EPS of $3.07 and revenue of $274.41 million. Despite insider sales of approximately $41.4 million in shares over the past 90 days, the stock opened at $132.04.
This article provides an institutional-grade analysis of Protagonist Therapeutics Inc. (NASDAQ: PTGX), highlighting a strong near-term sentiment shifting towards a long-term positive bias. It details an exceptional 41.3:1 risk-reward setup and outlines three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The analysis emphasizes real-time entry/exit signals, risk-reward ratios, and comprehensive risk management.
Protagonist Therapeutics (PTGX) is expected to announce its Q3 2026 earnings after market close on Thursday, November 5th, with analysts forecasting earnings of $2.50 per share and revenue of $238.49 million. The company exceeded expectations in its previous quarter, reporting $2.29 EPS and $213.47 million in revenue, a significant year-over-year increase. Despite a consensus "Buy" rating and a $163.27 price target from analysts, insiders have sold approximately $41.4 million worth of stock over the last 90 days.